TriLink BioTechnologies
Specialty Oligonucleotides and Nucleoside Triphosphates
TriLink offers cutting edge services to researchers in the fields of gene therapy, nucleoside chemotherapy, oligonucleotide therapy and diagnostics. TriLink specializes in the modification of oligonucleotides and nucleoside triphosphates. We provide a wide range of services from radioactive labeling to conjugation to custom research.
TriLink manufactures the world’s most extensive line of specialty nucleoside triphosphates. We carry over 120 modified nucleotides. TriLink was founded in 1996 to provide the biopharmaceutical research and industrial communities with high quality products and services that are not readily available elsewhere today.
The three founders of TriLink have over five decades of cumulative experience in the synthesis and labeling of modified oligonucleotides and nucleosides.